title: Second look laparotomy in the management of malignant epithelial ovarian neoplasias.
abstract: In the present study we examined 15 patients with malignant epithelial ovarian neoplasms who underwent primary surgery and chemotherapy at the Institute of Obstetric and Gynecologic Clinic of the University of Pisa between 1983 and 1985. At the time of diagnosis and monthly during chemotherapy plasma levels of CEA, CA 19-9, CA 125 and TPA were detected. At the end of pharmacological treatment a second-look laparotomy was performed in each patient to assess the status of cancer. At this time the clinical response was complete in 13 patients and partial in 2. These results were confirmed at second-look laparotomy in 11 of 13 cases of complete clinical remission and in 1 of the 2 cases of partial clinical remission. Two patients in complete clinical remission showed persistent disease. The other one in partial clinical remission was surgically found to have unmodified tumor. Tumoral markers, and especially CA 125, have a good correlation with the clinical course of the disease. However these tumor associated antigens cannot replace second-look laparotomy for assessing the response to cytostatic drugs. In fact patients with normal serum levels of these markers at the end of chemotherapy, were surgically found to have both complete pathological remission and persistent disease. Therefore we have come to the conclusion that the second-look laparotomy and the evaluation of tumor markers have to be performed together in the management of malignant ovarian neoplasms.
authors.forename: V
authors.initials: V
authors.lastname: Facchini
authors.forename: A
authors.initials: A
authors.lastname: Gadducci
authors.forename: B
authors.initials: B
authors.lastname: Del Bravo
authors.forename: L
authors.initials: L
authors.lastname: Colombi
authors.forename: T
authors.initials: T
authors.lastname: Bartolini
authors.forename: C
authors.initials: C
authors.lastname: Manfredini
authors.forename: P
authors.initials: P
authors.lastname: Fioretti
mesh_terms: D000368:Aged; D000951:Antigens, Neoplasm / Q000032:analysis; D015295:Antigens, Tumor-Associated, Carbohydrate; D000956:Antigens, Viral / Q000032:analysis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy / Q000276:immunology / Q000473:pathology / Q000601:surgery*; D005260:Female; D006801:Humans; D017874:Immediate-Early Proteins; D007813:Laparotomy; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000473:pathology / Q000601:surgery*; D010455:Peptides / Q000032:analysis; D019396:Tissue Polypeptide Antigen
chemical_list: D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate; D000956:Antigens, Viral; D017874:Immediate-Early Proteins; D010455:Peptides; D019396:Tissue Polypeptide Antigen; C044582:immediate-early proteins, cytomegalovirus